Buscar
Halozyme Therapeutics Inc
HALOAñadir a la lista de seguimiento
112.450USD
+2.770+2.53%
Cierre 09-18 16:00（ET）
12.84BCap. mercado
38.10P/E TTM
Más Datos de Halozyme Therapeutics Inc Compañía
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Perfil de Halozyme Therapeutics Inc
Símbolo de cotizaciónHALO
Nombre de la empresaHalozyme Therapeutics Inc
Fecha de salida a bolsaJan 30, 2003
Director ejecutivoTorley (Helen I)
Número de empleados350
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 30
Dirección12390 El Camino Real
CiudadSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92130
Teléfono18587948889
Sitio Webhttps://www.halozyme.com/
Símbolo de cotizaciónHALO
Fecha de salida a bolsaJan 30, 2003
Director ejecutivoTorley (Helen I)
Ejecutivos de Halozyme Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
767.78K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
58.84K
-32.28%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
38.49K
--
Ms. Cortney Caudill
Ms. Cortney Caudill
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
7.05K
-103.63%
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Independent Director
Independent Director
4.68K
+81.02%
Ms. Dannielle Appelhans
Ms. Dannielle Appelhans
Director
Director
1.16K
--
Mr. Jeffrey W. (Jeff) Henderson
Mr. Jeffrey W. (Jeff) Henderson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Bernadette Mary Connaughton
Ms. Bernadette Mary Connaughton
Independent Director
Independent Director
--
--
Mr. Mark Snyder
Mr. Mark Snyder
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
--
--
Ms. Moni Miyashita
Ms. Moni Miyashita
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Helen I. Torley
Dr. Helen I. Torley
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
767.78K
--
Mr. Matthew L. (Matt) Posard
Mr. Matthew L. (Matt) Posard
Independent Director
Independent Director
58.84K
-32.28%
Ms. Nicole Labrosse
Ms. Nicole Labrosse
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
38.49K
--
Ms. Cortney Caudill
Ms. Cortney Caudill
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
7.05K
-103.63%
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Independent Director
Independent Director
4.68K
+81.02%
Ms. Dannielle Appelhans
Ms. Dannielle Appelhans
Director
Director
1.16K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Halozyme Therapeutics Inc?
Los cinco principales accionistas de Halozyme Therapeutics Inc son: Dr. Helen I. Torley
¿Cuántas instituciones poseen acciones de Halozyme Therapeutics Inc (HALO)?
A fecha de 2026Q1, 1232 instituciones poseen acciones de Halozyme Therapeutics Inc, con un valor de mercado combinado de aproximadamente 138.78M, lo que representa el 117.14% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 5105303.00.
¿Cuál es la mayor fuente de ganancias de Halozyme Therapeutics Inc?
El 2026Q1, el segmento empresarial Royalties generó la ganancia más alta para Halozyme Therapeutics Inc, ascendiendo a 307.70M y representando el 63.97% de la ganancia total.